Affordable Access

deepdyve-link
Publisher Website

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

Authors
  • Andreano, Emanuele1
  • Nicastri, Emanuele2
  • Paciello, Ida1
  • Pileri, Piero1
  • Manganaro, Noemi1
  • Piccini, Giulia3
  • Manenti, Alessandro3, 4
  • Pantano, Elisa1
  • Kabanova, Anna1, 5
  • Troisi, Marco1, 6
  • Vacca, Fabiola1, 6
  • Cardamone, Dario1, 7
  • De Santi, Concetta1
  • Torres, Jonathan L.8
  • Ozorowski, Gabriel8
  • Benincasa, Linda4
  • Jang, Hyesun9
  • Di Genova, Cecilia10
  • Depau, Lorenzo11
  • Brunetti, Jlenia11
  • And 15 more
  • 1 Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy
  • 2 National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy
  • 3 VisMederi S.r.l, Siena, Italy
  • 4 VisMederi Research S.r.l., Siena, Italy
  • 5 Tumour Immunology Unit, Fondazione Toscana Life Sciences, Siena, Italy
  • 6 Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy
  • 7 University of Turin, Turin, Italy
  • 8 Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
  • 9 Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA
  • 10 Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Chatham, UK
  • 11 MedBiotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy
  • 12 Department of Medical Biotechnologies, University of Siena, Siena, Italy
  • 13 Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy
  • 14 Department of Infectious Diseases, University of Georgia, Athens, GA 30602, USA
  • 15 Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
  • 16 Faculty of Medicine, Imperial College, London, UK
Type
Published Article
Journal
Cell
Publisher
Elsevier Inc.
Publication Date
Feb 23, 2021
Identifiers
DOI: 10.1016/j.cell.2021.02.035
PMID: 33667349
PMCID: PMC7901298
Source
PubMed Central
Keywords
License
Unknown

Abstract

Extremely potent neutralizing human monoclonal antibodies, though rare, are isolated from COVID-19 convalescent patients and suitable for prophylactic and therapeutic interventions of wild-type SARS-CoV-2 as well as emerging variants.

Report this publication

Statistics

Seen <100 times